News | March 13, 2025
Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
The MDR certification reafirms that these products meet the highest safety, quality, and regulatory standards
Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies
Announces Rs. 317 crore investment in new recycling plant
The new lenders – JP Morgan, HSBC, and Barclays provided fresh funding
This MoU marks a significant milestone in interdisciplinary research, paving the way for scientific advancements in homoeopathy
Overall investment in the US facility is estimated around US$50 million
Vidya will spark conversations around less discussed and important aspects of health, including intimate care and sleep issues
403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
Subscribe To Our Newsletter & Stay Updated
